NUV-868 Alone and in Combination With PARP Inhibitors in Patients With Advanced Solid Tumors identifier:
NCT05252390 (

Treatment study for people with advanced solid tumors, including triple-negative breast, ovarian, pancreatic and prostate cancer

Study Contact Information:

Clinical Trials at Nuvation Bio by phone: 332-208-6102 

or by email: [email protected]

About the Study

This study will test how safe and effective the experimental drug NUV-868 is by itself and in combination with a PARP inhibitor in people with advanced solid tumors. The first part of the study will include people with any solid tumor type, and the second part will include people with triple-negative breast, ovarian, pancreatic or prostate cancers only. 

Type of Study

This is an open-label study, meaning participants and their doctors will know which drug(s) are being given. The study will be run in different phases and will have different groups. The dose and combination of treatments participants receive will depend on their cancer type and when they enroll in the study.

What the Study Involves

This study will have different phases and groups.

All participants will receive the study drug NUV-868. The dose will vary based on when people enroll in the study. Some participants will receive a second drug in combination with NUV-868. The combination will depend on their cancer type and when they enrolled in the study.

Participants will continue treatment unless their cancer gets worse, they develop serious side-effects, they decide to stop participating or the study is stopped.

The duration of the trial is expected to be 12 months.

Study Sites



North Carolina


This Study is Open To:

Phase 1 is open to people with advanced solid tumors whose cancer has progressed during or after treatment with approved therapies or for which there is no standard effective treatment available. 

Phase 2 is open to people diagnosed with the following advanced or metastatic cancers:

This Study is Not Open To:


FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.